Heart Transplantation for Cardiomyopathy - therapeutic Gold Standard?
The number of heart transplantations steadily increased worldwide during the 1980s and has plateaued since 1990 around 3500-4000 annually performed procedures. Meanwhile, more than 48000 such interventions have been reported during the last 20 years . Improved immunosuppression, antibiotic, and antimycotic therapies have led to better survival and longterm results even in patients with multiple concomitant diseases. Thus, cardiac transplantation has evolved from an experimental procedure to the therapeutic gold standard for patients with end-stage heart failure, refractory to medical treatment. Limitations of this procedure are evident with lack of available donor organs, side effects of immunosuppression (e.g., hypertension, renal insufficiency, osteoporosis) as well as an increased malignancy rate and chronic allograft rejection being the most predominant. Alternatively, new organ preserving surgical strategies as well as mechanical cardiac support devices have evolved, aiming at improvements in patient symptoms and quality of life as well as survival. Evaluation of all these techniques has to be balanced carefully against the results achieved with heart transplantation during the last two decades. The aim of this article is to present our management combined with long-term results in this patient group.
KeywordsDepression Ischemia Lymphoma Osteoporosis Creatinine
Bhatia SJS, Kirshenbaum JM, Shemin RJ, Cohn LH, Collins JJ, Di Sesa VJ, Young PI, Mudge GH, Sutton MGSJ (1987) Time course of resolution of pulmonary hypertension and right ventricular remodelling after orthotopic cardiac transplantation. Circulation 76:819–826PubMedCrossRefGoogle Scholar
Constanzo-Nordin MR, Cooper DK, Jessup M, Renlund DG, Robinson JA, Rose EA (1993) Task Force 6: future developments. J Am Coll Cardiol 22:1–64CrossRefGoogle Scholar
Devereux RB, Reichek N (1977) Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977, 55:613–18PubMedCrossRefGoogle Scholar
Fraund S, Pethig K, Franke U, Wahlers T, Harringer W, Cremer J, Fieguth HG, Op-pelt P, Haverich A (1999) Ten-year-survival after heart transplantation: palliative procedure or successful long term treatment? Heart 82:47–51PubMedGoogle Scholar
Gill EA, Borrego C, Bray B, Renlund DG, Hammond E, Gilbert EM (1995) Left ventricular mass increases during cardiac allograft vascular rejection. J Am Coll Cardiol 25:922–926PubMedCrossRefGoogle Scholar
Hetzer R, Albert W, Hummel M, Pasic M, Loebe M, Warnecke H, Haverich A, Borst HG (1997) Status of patients presently living 9 to 13 years after orthotopic heart transplantation. Ann Thorac Surg 64:1661–1668PubMedCrossRefGoogle Scholar
Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ (1999) The Registry of the International Society for Heart and Lung Transplantation: sixteenth official report - 1999. J Heart Lung Transplant 18:611–626PubMedCrossRefGoogle Scholar
Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR (1991) Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83:778–786PubMedCrossRefGoogle Scholar
Miller LW, Schlant R, Kobashigawa J, Spencer K, Renlund DG (1993) Task Force 5: Complications. J Am Coll Cardiol 22:1–64CrossRefGoogle Scholar
Pethig K, Besser K, Heublein B, Wahlers T, Harringer W, Haverich A (1999) Coronary vasculopathy after heart transplantation - effect of temporal onset, severity and progression on long-term prognosis. Z Kardiol 88:498–506PubMedCrossRefGoogle Scholar
Robbins R, Barlow C, Oyer P, Hunt SA, Miller L, Reitz BA, Stinson E, Shumway E (1999) Thirty years of cardiac transplantation at Stanford University. J Thorac Cardiovasc Surg 117:939–951PubMedCrossRefGoogle Scholar
Schirmer H, Linde P, Rasmussen K (1999) Prevalence of left ventricular hypertrophy in a general population. Eur Heart J 6:429–436CrossRefGoogle Scholar
© Springer-Verlag Berlin Heidelberg 2000